Ultragenyx CFO’s June 1 Sale Adds to Insider Sell‑Trend, But Stock’s Rare‑Disease Pipeline Keeps Investor Optimism Alive
Ultragenyx CFO’s recent insider sale: 4,653 shares at $23.77 amid a modest decline—why it matters for long‑term investors and the company’s rare‑disease pipeline.
- ULTRAGENYX PHARMACEUTICAL IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read